MCID: HPT003
MIFTS: 63

Hepatitis a

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Rare diseases, Skin diseases

Aliases & Classifications for Hepatitis a

MalaCards integrated aliases for Hepatitis a:

Name: Hepatitis a 12 74 42 43 15 71
Viral Hepatitis, Type a 12
Viral Hepatitis a 12

Classifications:



External Ids:

Disease Ontology 12 DOID:12549
MeSH 43 D006506
NCIt 49 C3096
SNOMED-CT 67 40468003
ICD10 32 B15.0 B15.9
UMLS 71 C0019159

Summaries for Hepatitis a

MedlinePlus : 42 Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. Hepatitis is an inflammation of the liver. One type, hepatitis A, is caused by the hepatitis A virus (HAV). The disease spreads through contact with an infected person's stool. You can get it from Eating food made by an infected person who did not wash their hands after using the bathroom Drinking untreated water or eating food washed in untreated water Putting into your mouth a finger or object that came into contact with an infected person's stool Having close contact with an infected person, such as through sex or caring for someone who is ill Most people do not have any symptoms. If you do have symptoms, you may feel as if you have the flu. You may also have yellowish eyes and skin, called jaundice. A blood test will show if you have HAV. HAV usually gets better in a few weeks without treatment. However, some people can have symptoms for up to 6 months. Your doctor may suggest medicines to help relieve your symptoms. The hepatitis A vaccine can prevent HAV. Good hygiene can also help. Wash your hands thoroughly before preparing food, after using the toilet, or after changing a diaper. International travelers should be careful about drinking tap water. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Hepatitis a, also known as viral hepatitis, type a, is related to acute liver failure and fatty liver disease, and has symptoms including fever, vomiting and fatigue. An important gene associated with Hepatitis a is HAVCR1 (Hepatitis A Virus Cellular Receptor 1), and among its related pathways/superpathways are Cytokine Signaling in Immune system and PI3K-Akt signaling pathway. The drugs Neomycin and Pentoxifylline have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and kidney, and related phenotypes are cardiovascular system and homeostasis/metabolism

Disease Ontology : 12 A viral infectious disease that results in inflammation located in liver, has material basis in Hepatitis A virus, which is transmitted by ingestion of contaminated food or water, or transmitted by direct contact with an infected person. The infection has symptom fever, has symptom fatigue, has symptom loss of appetite, has symptom nausea, has symptom vomiting, has symptom abdominal pain, has symptom clay-colored bowel movements, has symptom joint pain, and has symptom jaundice.

Wikipedia : 74 Hepatitis A is an infectious disease of the liver caused by Hepatovirus A (HAV). Many cases have few or... more...

Related Diseases for Hepatitis a

Diseases in the Hepatitis family:

Hepatitis C Virus Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis B Hepatitis D
Autoimmune Hepatitis Hepatitis E
Autoimmune Hepatitis Type 2 Autoimmune Hepatitis Type 1

Diseases related to Hepatitis a via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 848)
# Related Disease Score Top Affiliating Genes
1 acute liver failure 32.6 GPT F2 ALB
2 fatty liver disease 32.2 TNF TLR4 GPT GGT1 ALB
3 hepatitis e 31.9 TNF TLR3 IFNG GPT GGT1 F2
4 hepatitis d 31.0 IFNA1 GPT F2
5 acute kidney failure 31.0 HAVCR1 GPT F2 ALB
6 hepatic coma 30.9 GPT F2 ALB AFP
7 cutaneous leishmaniasis 30.8 TNF TLR4 IL2 IL10 IFNG
8 hepatitis 30.8 TNF TICAM1 SEPSECS MAVS IKBKG IFNG
9 drug-induced hepatitis 30.8 TNF GPT ALB
10 acalculous cholecystitis 30.8 GPT F2 ALB
11 hepatic encephalopathy 30.8 TNF GPT F2 ALB
12 cholestasis 30.8 GPT GGT1 F2 CYP3A4 ALB
13 acute kidney tubular necrosis 30.7 HAVCR1 GGT1 ALB
14 poliomyelitis 30.7 TNF IL10 IFNG AFP
15 hepatorenal syndrome 30.6 HAVCR1 GPT F2 ALB
16 gastroenteritis 30.5 TNF IL10 IFNG IFNA1 ALB
17 cholecystitis 30.5 TLR4 GPT F2 ALB
18 liver disease 30.5 TNF SEPSECS IFNA1 GPT GGT1 F3
19 red cell aplasia 30.4 IL2 IFNA1 ALB
20 autoimmune hepatitis 30.4 TNF SEPSECS IL10 IFNA1 GPT GGT1
21 pure red-cell aplasia 30.4 IL2 IFNA1 ALB
22 acute pancreatitis 30.4 TNF TLR4 IL10 GPT ALB
23 meningoencephalitis 30.4 TNF IL10 ALB
24 dengue disease 30.4 TNF GPT ALB
25 non-alcoholic steatohepatitis 30.3 TNF GPT GGT1
26 alcoholic hepatitis 30.3 TNF TLR4 IL10 GPT GGT1 F2
27 viral hepatitis 30.2 TNF TLR4 TLR3 SEPSECS IL2 IL10
28 diphtheria 30.2 TNF IL2 IFNG ALB
29 neuritis 30.2 TNF IL10 IFNG
30 cryoglobulinemia 30.1 TNF IL10 IFNG IFNA1 GPT
31 thyroiditis 30.1 TNF IL2 IL10 IFNA1
32 eclampsia 30.1 TNF F2 ALB
33 tetanus 30.1 TNF IL2 IL10 IFNG ALB
34 typhoid fever 30.1 TNF TLR4 IFNG GPT GGT1 F2
35 infantile liver failure syndrome 1 30.1 GPT F2 ALB
36 hemophagocytic lymphohistiocytosis 30.0 TNF IL10 IFNG GPT
37 chronic graft versus host disease 30.0 IL10 IFNG ALB
38 newcastle disease 30.0 TNF TLR3 IFNA1
39 encephalitis 30.0 TNF TLR3 TICAM1 IL10
40 hypereosinophilic syndrome 30.0 IL2 IL10 IFNG IFNA1
41 rabies 30.0 TLR3 IFNA1 ALB
42 kawasaki disease 30.0 TNF IL10 GPT ALB
43 autoimmune disease 29.9 TNF IL2 IL10 IFNG IFNA1 HAVCR2
44 polyradiculoneuropathy 29.9 IL10 IFNG ALB
45 pericarditis 29.9 TNF IFNG ALB
46 purpura 29.9 TNF IL10 F3 F2
47 chickenpox 29.9 TNF TLR3 IL2 IL10 IFNG ALB
48 mouth disease 29.9 TLR4 TLR3 IL10 IFNG IFNA1
49 multifocal choroiditis 29.9 TNF IL10
50 cholelithiasis 29.9 GPT GGT1 ALB

Graphical network of the top 20 diseases related to Hepatitis a:



Diseases related to Hepatitis a

Symptoms & Phenotypes for Hepatitis a

Symptoms:

12
  • fever
  • vomiting
  • fatigue
  • abdominal pain
  • jaundice
  • nausea
  • loss of appetite
  • joint pain
  • clay-colored bowel movements

UMLS symptoms related to Hepatitis a:


nausea and vomiting, constipation, fever, abdominal pain, pruritus, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas

MGI Mouse Phenotypes related to Hepatitis a:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.32 ALB F2 F3 HAVCR2 IFNG IKBKG
2 homeostasis/metabolism MP:0005376 10.3 AFP ALB F2 F3 GGT1 IFNG
3 hematopoietic system MP:0005397 10.29 F2 F3 GGT1 HAVCR2 IFNG IKBKG
4 immune system MP:0005387 10.28 ALB F2 F3 GGT1 HAVCR2 IFNG
5 mortality/aging MP:0010768 10.2 AFP ALB F2 F3 GGT1 HAVCR2
6 digestive/alimentary MP:0005381 10.19 ALB F2 IFNG IKBKG IL10 IL2
7 integument MP:0010771 10.06 F2 F3 GGT1 IFNG IKBKG IL10
8 liver/biliary system MP:0005370 10.02 AFP ALB IFNG IKBKG IL10 IL2
9 neoplasm MP:0002006 9.9 AFP ALB F3 IFNG IKBKG IL10
10 muscle MP:0005369 9.86 ALB F3 IFNG IL10 MAVS TLR3
11 reproductive system MP:0005389 9.65 AFP F2 GGT1 IFNG IKBKG IL10
12 respiratory system MP:0005388 9.28 F2 F3 IFNG IL10 IL2 MAVS

Drugs & Therapeutics for Hepatitis a

Drugs for Hepatitis a (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 483)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
2
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
3
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
4
Ezetimibe Approved Phase 4 163222-33-1 150311
5
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
6
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
7
Rifampicin Approved Phase 4 13292-46-1 5381226 5458213
8
Pyrazinamide Approved, Investigational Phase 4 98-96-4 1046
9
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
10
Methadone Approved Phase 4 76-99-3 4095
11
Acetylcarnitine Approved, Investigational Phase 4 3040-38-8 7045767
12
Nitazoxanide Approved, Investigational, Vet_approved Phase 4 55981-09-4 41684
13
Ledipasvir Approved Phase 4 1256388-51-8 67505836
14
Nelfinavir Approved Phase 4 159989-64-7 64143
15
Zidovudine Approved Phase 4 30516-87-1 35370
16
Milk thistle Approved, Experimental, Investigational Phase 4 65666-07-1
17
Losartan Approved Phase 4 114798-26-4 3961
18
Citalopram Approved Phase 4 59729-33-8 2771
19
Cobicistat Approved Phase 4 1004316-88-4
20
Metformin Approved Phase 4 657-24-9 4091 14219
21
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
22
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
23
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
24
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 23925 27284
25
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
26
Simethicone Approved Phase 4 8050-81-5
27
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
28
Colchicine Approved Phase 4 64-86-8 6167 2833
29
Adalimumab Approved Phase 4 331731-18-1 16219006
30
Etanercept Approved, Investigational Phase 4 185243-69-0
31
Lenograstim Approved, Investigational Phase 4 135968-09-1
32
Azathioprine Approved Phase 4 446-86-6 2265
33
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
34
Sargramostim Approved, Investigational Phase 4 83869-56-1, 123774-72-1
35
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
36
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
37
Nevirapine Approved Phase 4 129618-40-2 4463
38
glycyrrhizin Approved, Experimental Phase 4 1405-86-3 3495
39
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
40
Interferon alfacon-1 Approved, Investigational Phase 4 118390-30-0 9554198
41
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
42
tannic acid Approved Phase 4 1401-55-4
43
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
44
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
45
Mycophenolic acid Approved Phase 4 24280-93-1 446541
46
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
47
Zinc Approved, Investigational Phase 4 7440-66-6 32051
48
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
49
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
50
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840

Interventional clinical trials:

(show top 50) (show all 2418)
# Name Status NCT ID Phase Drugs
1 Prophylactic Use of Entecavir to Reduce Hepatitis Flare in Highly Viremic HBV Patients With Active Tuberculosis Receiving Anti-tuberculous Treatment Unknown status NCT01724723 Phase 4 entecavir (BARACLUDE®)
2 Comparative Immunogenicity Study of Two Live Attenuated Hepatitis A Vaccines Unknown status NCT03231605 Phase 4
3 A Study Comparing the Effectiveness of Two Different Vaccination Schedules of the Combined Hepatitis A and B Vaccine(Twinrix Adult1440/20) Unknown status NCT00216229 Phase 4
4 Immune Response to Pneumococcal Conjugate Vaccine in Adults Receiving Hepatitis A Vaccine at the Same Time Unknown status NCT01926860 Phase 4
5 Cellular Immunity in Adult Hepatitis B-vaccinated Serologic Non-responders Unknown status NCT01451801 Phase 4
6 Efficacy and Safety of Daclatasvir Plus Asunaprevir Treatment in Patients With Chronic Hepatitis C : Prospective Cohort Study Unknown status NCT02639585 Phase 4 Daclinza and Sunvepra
7 Active Drug Comparative Trial to Evaluate the Antiviral Activity and Safety in Chronic Hepatitis B Patients Unknown status NCT02588937 Phase 4 EntecaBell ODT. 0.5mg;Baraclude Tab. 0.5mg
8 Study to Identify Eligible Subjects Using Response Guided Therapy-Stopping Rule for Treatment of Pegylated Interferon Alfa 2a(Pegasys®) in the Korean Chronic Hepatitis B(CHB) Adults. Unknown status NCT02822547 Phase 4 Peginterferon alfa-2a
9 Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients Unknown status NCT02327702 Phase 4 Emtricitabine
10 PhaseIVstudy to Evaluate the Non-inferiority of Cavir®Tab. in Terms of Hepatitis B Virus(HBV)DNA Undetectability Comparing Baraclude® Tab. in Hepatitis B e Antigen(HBeAg)(+) Chronic Hepatitis B Patients Treated With Long-term Baraclude® Tab Unknown status NCT02523547 Phase 4 Cavir;Baraclude
11 Efficacy of Long-term Telbivudine Treatment on Histological Improvements in Patients With Chronic Hepatitis B (EFFORT Further Extension Study) Unknown status NCT02826070 Phase 4 Telbivudine;Adefovir dipivoxil
12 Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients Unknown status NCT02327676 Phase 4 Emtricitabine
13 Efficacy of Antiviral Therapy With Lamivudine or Entecavir After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma Unknown status NCT00768157 Phase 4 antiviral treatment (lamivudine or entecavir)
14 Effects of Short-term Atorvastatin Treatment on Vaccination Efficacy in Nonresponder Persons to Hepatitis B Vaccine Unknown status NCT01548326 Phase 4 Atorvastatin;placebo
15 Efficacy and Safety of S-adenosyl-l-methionine in Treatment of Alcoholic Hepatitis With Cholestasis Unknown status NCT02024295 Phase 4 Ademethionine;Polyene Phosphatidyl choline;Ademethionine
16 AN OPEN STUDY OF LAMIVUDINE TREATMENT IN ADULT HBeAg NEGATIVE (Presumed Pre-Core Mutant) CHRONIC HEPATITIS B PATIENTS IN IRAN. Unknown status NCT00354653 Phase 4 LAMIVUDINE
17 Hepatitis C in Renal Transplant Recipients - Safety and Efficacy of a Conversion of Immunosuppression to High-dose Cyclosporine A and Its Impact on Hepatitis C Virus-replication, Parameters of Liver Function and Glucose Tolerance. An Open Label Trial. Unknown status NCT02108301 Phase 4 tacrolimus-cyclosporine A
18 A Randomized, Multi-center, Phase IV Open-label Study Evaluating the Antiviral Efficacy of Addition of Vitamin D in Patients With Treatment Naïve Chronic Hepatitis C Receiving Peginterferon Alfa-2a Plus Ribavirin Unknown status NCT01439776 Phase 4
19 A Multi-center, Open Label, Randomized Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Capsule Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Unknown status NCT01436539 Phase 4 Adefovir Dipivoxil and polyene phosphatidylcholine;Adefovir Dipivoxil
20 Efficacy and Safety of Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With Chronic Hepatitis B Who Have Resistant Mutants to Lamivudine and Show Suboptimal Response to Combination of Lamivudine Plus Adefovir or Adefovir Monotherapy Unknown status NCT02482272 Phase 4 Lamivudine;Adefovir;Entecavir
21 Grazoprevir/Elbasvir for Treatment of Hepatitis C Virus Genotype 4 Post Kidney Transplant Unknown status NCT03359746 Phase 4 Grazoprevir/Elbasvir
22 Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis Unknown status NCT01998620 Phase 4 Ademetionine 2;Ademetionine 1;Ademetionine 3
23 Clinical Study of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B Unknown status NCT01380951 Phase 4 telbivudine
24 Immunogenicity and Safety of High-dose Hepatitis B Vaccine Among Drug Users: a Randomized, Controlled Trial Unknown status NCT02959775 Phase 4
25 A Multi-center, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Generic Entecavir Monotherapy or in Combination With Adefovir for Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy Unknown status NCT01341743 Phase 4 Entecavir;Entecavir, Adefovir;Entecavir, Adefovir
26 A Pilot Study Evaluating the Combination Hepatitis A and B Vaccine (Twinrix®) in Healthy Healthcare Workers Who Meet the CDC Definition for Non-responders. Unknown status NCT01126853 Phase 4
27 Emtricitabine for Naive Chinese Chronic Hepatitis B Patients Unknown status NCT02327663 Phase 4 Emtricitabine
28 The Efficacy and Safety of the Anti Hepatitis B Placenta Transfer Factor Injection in the Treatment of HBeAg Positive Chronic Hepatitis B, Randomized, Double Blind, Placebo Controlled, Multi Center Clinical Trial Unknown status NCT02412319 Phase 4 Anti-HBV placenta transfer factor injection
29 A Multi Center, Phase IIIb Study to Evaluate the Efficacy of Response Guided Therapy Using Quantitative HBsAg Measurement in Patient With HBeAg Positive Chronic Hepatitis B: Unknown status NCT01456312 Phase 4 Peginterferon alfa-2a;Entecavir
30 Treatment of Chronic Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels With Peginterferon α-2a (40 kDa) Plus Ribavirin Unknown status NCT00575627 Phase 4 Peg-Interferon alpha2a plus Ribavirin
31 Immunogenicity and Persistence of Intramuscular High Dose Recombinant Hepatitis B Vaccine in HIV-infected Adults in China Unknown status NCT03316807 Phase 4
32 Investigation on Antiviral Therapy of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B Patients Based on Detection of Interferon Gene Mutation and Interferon Receptor Unknown status NCT02973646 Phase 4 Entecavir or Tenofovir;Peginterferon Alfa-2B
33 Comparison of Antiviral Efficacy of Entecavir Monotherapy and Combination Treatment With Poly IC for Chronic Hepatitis B Unknown status NCT02532413 Phase 4 Poly IC;Entecavir
34 A Pilot Study to Assess the Efficacy and Safety of Folic Acid and/or Vitamin B Complex on Hepatitis C Infected Patients Treated With Pegylated Interferon and Ribavirin. Unknown status NCT02150291 Phase 4 Neurobion;placebo
35 A Study of Efficacy and Safety of Telbivudine in Pregnancy for the Prevention of Perinatal Transmission of Hepatitis B Virus Infection Unknown status NCT00939068 Phase 4 Telbivudine
36 Toward Elimination of Hepatitis C Virus (HCV): A Pilot Study Combining HCV and Addiction Treatment of Young Suburban Heroin Users (SHU) That Addresses Barriers to Care Unknown status NCT03364725 Phase 4 Glecaprevir-pibrentasvir
37 Immunogenicity and Reactogenicity of 10-valent Pneumococcal Conjugate Vaccine (PCV10) in Children Aged 12-59 Months Unknown status NCT01028326 Phase 4
38 Immunogenicity and Persistence of Intramuscular High Dose Recombinant Hepatitis B Vaccine in Hemodialysis Patients in China: a Multicenter Randomized Controlled Trial Unknown status NCT02963714 Phase 4
39 Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma Unknown status NCT01765231 Phase 4 Entecavir prophylaxis;Observation arm
40 Analysis of Proximal Renal Tubular Function of "Real World" Chronic Hepatitis B (CHB) Patients Who Are Suppressed on TDF and Switched to TAF Unknown status NCT02957994 Phase 4 Tenofovir alafenamide fumarate
41 A Prospective, Open-label, Multicenter Study of Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral Agents Unknown status NCT02337127 Phase 4 Lamivudine
42 Efficacies of Entecavir Add on HBeAg Negative Chronic Hepatitis B Patients With HBV DNA Load ≥1000 Copies/ml After 3 Months of Peginterferon Alpha 2a Treatment Unknown status NCT02365402 Phase 4 Entecavir
43 Randomized, Multi-Center, Partially Placebo-Controlled Phase IV-Study to Compare Efficacy and Tolerability of 48-Week Combined Therapy With Peginterferon Alfa-2a, Ribavirin and Amantadine Sulphate Versus Placebo in Untreated Patients With Chronic Hepatitis C Virus-Genotype-1-Infection Unknown status NCT00127777 Phase 4 Amantadine sulphate (in addition to standard treatment)
44 A Prospective, Randomized, Controlled Clinical Trial to Evaluate the Role of Peg-IFN Alfa-2a in Reducing RelapSe Rate in Patients With Hepatitis B e Antigen(HBeAg)-nEgative Chronic Hepatitis B After Discontinuation of NUC Therapy Unknown status NCT02594293 Phase 4 PegIFN alfa-2a
45 Open, Randomized and Multicenter Phase IV Study to Compare the Efficacy and Safety of Two Different Treatments Duration 24 Versus 48 Weeks in Chronic Hepatitis C Genotypes 2 and/or 3 co-Infected HIV-HCV Patients. Unknown status NCT00611819 Phase 4 Peg interferon + Ribavirin;Peg interferon + Ribavirin
46 Immunologic Response of Hepatitis B Single Dose Versus 3-dose Series in Previously Vaccinated HIV-infected Adults at Maharaj Nakorn Chiang Mai Hospital: A Randomized Controlled Trial Unknown status NCT03219203 Phase 4
47 Sustained Off-treatment Response After HBeAg Loss in HBeAg-Pos Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues Unknown status NCT01911156 Phase 4 Continue NA treatment;Discontinue NA Treatment
48 Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Hepatitis B e Antigen-positive Patients With Chronic Hepatitis B Unknown status NCT01906580 Phase 4 Peg-IFNα-2a;Entecavir
49 The Response and Outcomes of Pegylated Interferon Plus Ribavirin Combination Therapy for Chronic Hepatitis C Patients Concomitant With Hepatocellular Carcinoma Unknown status NCT00834860 Phase 4 peginterferon alpha-2a and ribavirin
50 A Randomized, Open Label, Phase IV, Multicenter Study for Efficacy and Safety of Lamivudine Versus Entecarvir Therapy in HBV-related Advanced Liver Disease Patients With High Viral Load and Normal or Slightly Elevated Transaminase Unknown status NCT00823550 Phase 4 Entecavir;Lamivudine

Search NIH Clinical Center for Hepatitis a

Cochrane evidence based reviews: hepatitis a

Genetic Tests for Hepatitis a

Anatomical Context for Hepatitis a

The Foundational Model of Anatomy Ontology organs/tissues related to Hepatitis a:

19
Liver

MalaCards organs/tissues related to Hepatitis a:

40
Liver, Testes, Kidney, T Cells, Bone, Lung, B Cells

Publications for Hepatitis a

Articles related to Hepatitis a:

(show top 50) (show all 11994)
# Title Authors PMID Year
1
Lack of Correlation Between Serum Ferritin Levels and Patient Outcome in Israeli Adults with Hepatitis A Infection. 61 42
31599510 2019
2
Impact of Public Health Interventions on Drinking Water-Associated Outbreaks of Hepatitis A - United States, 1971-2017. 61 42
31487277 2019
3
Causes and countermeasures for repeated outbreaks of hepatitis A among adults in Korea. 61 42
31715685 2019
4
Hepatitis A Virus Genotype IB Outbreak among Internally Displaced Persons, Syria. 61
31829918 2020
5
2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. 61
31413005 2020
6
Role of high-volume plasma exchange in a case of a G6PD deficient patient presenting with HAV related acute liver failure and concomitant acute renal failure. 61
31757665 2019
7
Recreational drugs and STI diagnoses among patients attending an STI/HIV reference clinic in Rome, Italy. 61
31101722 2019
8
Time to act to make elimination of viral hepatitis a reality. 61
31852633 2019
9
Recovery from hepatitis A after Korean medicine-based treatment : a case report. 61
31768311 2019
10
Acute Viral Hepatitis: Simultaneous Infection from Hepatitis A, B and E Viruses. 61
31779757 2019
11
Concentration of hepatitis A virus in milk using protamine-coated iron oxide (Fe3O4) magnetic nanoparticles. 61
31421754 2019
12
The pathogenicity of duck hepatitis A virus types 1 and 3 on ducklings. 61
31393586 2019
13
Sarcopenia is associated with longer hospital stay and multiorgan dysfunction in alcoholic hepatitis. 61
31834050 2019
14
Hepatitis A immunisation in persons not previously exposed to hepatitis A. 61
31846062 2019
15
Hepatitis A Outbreaks in Developed Countries: Detection, Control, and Prevention. 61
31829731 2019
16
Vestibular Hyperreflexia and Opsoclonus in Acute Hepatitis A Virus Infection. 61
31154623 2019
17
Manufacturing of plasma-derived C1-inhibitor concentrate for treatment of patients with hereditary angioedema. 61
31796151 2019
18
Understanding temporal and spatial variations of viral disease in the US: The need for a one-health-based data collection and analysis approach. 61
31709295 2019
19
In-Situ Mutation Detection by Magnetic Beads-Probe Based on Single Base Extension and Its Application in Genotyping of Hepatitis B Virus Pre-C Region 1896nt Locus Single Nucleotide Polymorphisms. 61
31748019 2019
20
CXCL9 regulates acetaminophen-induced liver injury via CXCR3. 61
31772648 2019
21
Characteristics and current clinical practices of opioid treatment programs in the United States. 61
31678836 2019
22
Interlaboratory Comparative Study to Detect Potentially Infectious Human Enteric Viruses in Influent and Effluent Waters. 61
31154654 2019
23
Persistence of murine norovirus, bovine rotavirus, and hepatitis A virus on stainless steel surfaces, in spring water, and on blueberries. 61
31421763 2019
24
Visual Simultaneous Detection of Hepatitis A and B Viruses Based on a Multifunctional Molecularly Imprinted Fluorescence Sensor. 61
31718158 2019
25
Effectiveness of Single-Dose Administration of Inactivated Hepatitis A Virus Vaccination in the Republic of Korea Armed Forces, 2013-2016. 61
31854016 2019
26
Blood safety assessment of hepatitis A outbreak linked to frozen pomegranate arils: are foodborne outbreaks an emerging blood safety risk? 61
31642534 2019
27
Hydrophobicity and oligomerization are essential parameters for membrane penetration activity of the VP4 peptide from Hepatitis A Virus (HAV). 61
31711790 2019
28
Molecular Characterization and Phylogenetic Analysis of Enteroviruses and Hepatitis A Viruses in Sewage Samples, Northern Italy, 2016. 61
31420848 2019
29
[Travel vaccinations]. 61
31802155 2019
30
Antecedent infections in Guillain-Barré syndrome: a single-center, prospective study. 61
31714025 2019
31
Insufficient awareness and vaccination practices for inflammatory bowel disease patients in China: A multi-center survey of Chinese gastroenterologists. 61
31794121 2019
32
To err is human: Clinical incident calls to a national travel health advice line. 61
31611096 2019
33
Vaccination of healthcare personnel in Europe: Update to current policies. 61
31623916 2019
34
Vaccination coverage and its determinants of live attenuated hepatitis A vaccine among children aged 24-59 months in 20 rural counties of 10 provinces of China in 2016. 61
31746666 2019
35
Increasing Burden of Hepatitis A in Adolescents and Adults and the Need for Long-Term Protection: A Review from the Indian Subcontinent. 61
31679118 2019
36
Study of a hepatitis E virus outbreak involving drinking water and sewage contamination in Shimla, India, 2015-2016. 61
31647558 2019
37
Dissecting microbial community structure in sewage treatment plant for pathogens' detection using metagenomic sequencing technology. 61
31848653 2019
38
Prevention of Opportunistic Infections in Women With HIV Infection. 61
31433312 2019
39
Household transmission and disease transmissibility of a large HAV outbreak in Lazio, Italy, 2016-2017. 61
31326355 2019
40
Breaking down the barriers to a natural antiviral agent: Antiviral activity and molecular docking of Erythrina speciosa extract, fractions, and the major compound. 61
31800173 2019
41
Quantitative Proteomic Analysis Uncovers the Mediation of Endoplasmic Reticulum Stress-Induced Autophagy in DHAV-1-Infected DEF Cells. 61
31817666 2019
42
Development of an extraction method to detect enteric viruses in dressed vegetables. 61
31634688 2019
43
Adverse health effects of abuse-deterrent opioids: Evidence from the reformulation of OxyContin. 61
31715653 2019
44
A new solid matrix for preservation of viral nucleic acid from clinical specimens at ambient temperature. 61
31520683 2019
45
Involvement of Egyptian Foods in Foodborne Viral Illnesses: The Burden on Public Health and Related Environmental Risk Factors: An Overview. 61
31560123 2019
46
Infectious Disease Management and Control with Povidone Iodine. 61
31414403 2019
47
Polyphosphonium-oligochitosans decorated with nanosilver as new prospective inhibitors for common human enteric viruses. 61
31582052 2019
48
Seroprevalence of viral hepatitis A, B, C, D and E viruses in the Hormozgan province southern Iran. 61
31795979 2019
49
Hepatitis E Virus Infections Among Human Immunodeficiency Virus-Positive Individuals During an Outbreak of Acute Hepatitis A in Taiwan. 61
31100186 2019
50
The epidemiology of 32 selected communicable diseases in Iraq, 2004-2016. 61
31560993 2019

Variations for Hepatitis a

Expression for Hepatitis a

Search GEO for disease gene expression data for Hepatitis a.

Pathways for Hepatitis a

Pathways related to Hepatitis a according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.38 TNF IL2 IL10 IKBKG IFNG IFNA1
2
Show member pathways
13 TNF TLR4 TLR3 TICAM1 IL2 IKBKG
3
Show member pathways
12.95 TNF TLR4 TLR3 TICAM1 IKBKG IFNA1
4
Show member pathways
12.86 TNF IL2 IL10 IFNG IFNA1
5
Show member pathways
12.79 TNF TLR4 TLR3 TICAM1 MAVS IL2
6 12.77 TNF TLR3 TICAM1 MAVS IKBKG IFNG
7
Show member pathways
12.73 TNF TLR4 TLR3 IL2 IKBKG
8
Show member pathways
12.66 TNF IL2 IL10 IKBKG IFNG
9
Show member pathways
12.64 TNF TLR4 TLR3 TICAM1 MAVS IKBKG
10
Show member pathways
12.58 TNF TLR4 IL2 IL10 IKBKG IFNG
11
Show member pathways
12.57 TNF IL2 IL10 IKBKG IFNG F2
12
Show member pathways
12.56 TNF TLR4 TICAM1 IL2 IL10 IKBKG
13
Show member pathways
12.37 IL2 IL10 IFNG IFNA1
14 12.32 TNF TLR4 IKBKG F2
15
Show member pathways
12.32 TLR4 TLR3 TICAM1 IKBKG
16
Show member pathways
12.32 TNF IL2 IFNG GGT1 F2 ALB
17
Show member pathways
12.32 TNF TLR4 TLR3 TICAM1 MAVS IL2
18
Show member pathways
12.3 TNF TLR4 TLR3 TICAM1 IKBKG IFNG
19
Show member pathways
12.28 TNF IL2 IL10 IFNG IFNA1
20
Show member pathways
12.28 TNF TLR4 TLR3 TICAM1 IKBKG
21
Show member pathways
12.27 TNF TLR4 IL10 IKBKG IFNG
22
Show member pathways
12.24 TNF IL2 IL10 IKBKG
23 12.23 TNF TLR4 IL10 IFNG IFNA1
24 12.21 TNF TLR4 TLR3 IFNG
25
Show member pathways
12.21 TNF TLR4 IKBKG IFNG
26 12.19 TNF TLR4 TICAM1 MAVS IKBKG IFNA1
27
Show member pathways
12.12 TNF TLR4 TLR3 TICAM1 IFNG IFNA1
28
Show member pathways
12.06 TNF TLR4 IFNG F2
29
Show member pathways
12.05 TLR4 TLR3 IL2 IKBKG
30 12.03 TNF TLR4 IL2 IFNG
31 12.01 TNF IL2 IL10 IFNG
32 11.94 TNF TLR4 TICAM1 IKBKG
33 11.94 TNF TLR4 IL10 IFNG
34 11.91 IL2 IL10 IFNG IFNA1
35
Show member pathways
11.91 TNF TLR4 TLR3 IL2 IL10 IFNG
36 11.88 TNF TLR3 TICAM1 MAVS IL2 IL10
37 11.82 TNF IL2 IL10 IFNG
38 11.81 IL2 IFNG AFP
39 11.81 TNF TLR4 TICAM1 IL2 IL10 IKBKG
40 11.79 TNF TLR4 TICAM1 IL10
41
Show member pathways
11.78 TNF IL2 IFNG
42 11.78 TNF IL2 IL10 IFNG
43 11.74 TNF IL2 IL10 IFNG
44
Show member pathways
11.69 TNF IL2 IFNG
45
Show member pathways
11.67 TNF IL2 IFNG
46 11.61 TNF TLR4 IKBKG
47 11.58 TNF IL2 IFNG
48
Show member pathways
11.57 TNF IKBKG IFNG
49 11.55 TNF TLR4 IL10 IFNG
50 11.54 TNF TLR4 IFNG

GO Terms for Hepatitis a

Cellular components related to Hepatitis a according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 TNF IL2 IL10 IFNG IFNA1 F3
2 extracellular space GO:0005615 9.4 TNF TLR3 IL2 IL10 IFNG IFNA1

Biological processes related to Hepatitis a according to GeneCards Suite gene sharing:

(show top 50) (show all 65)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.27 TNF TLR4 TLR3 MAVS IL2 IL10
2 immune system process GO:0002376 10.19 TLR4 TLR3 TICAM1 MAVS IL2 HAVCR2
3 innate immune response GO:0045087 10.18 TLR4 TLR3 TICAM1 MAVS IKBKG HAVCR2
4 immune response GO:0006955 10.15 TNF TLR4 IL2 IL10 IKBKG IFNG
5 positive regulation of gene expression GO:0010628 10.13 TNF TLR4 TLR3 TICAM1 IFNG
6 cytokine-mediated signaling pathway GO:0019221 10.1 TNF IL2 IL10 IFNA1 F3
7 defense response to bacterium GO:0042742 10.06 TNF TLR4 TLR3 MAVS IL10
8 defense response to virus GO:0051607 10.02 TLR3 TICAM1 MAVS IFNG IFNA1
9 response to lipopolysaccharide GO:0032496 10.01 TLR4 TICAM1 IL10 GGT1
10 positive regulation of protein phosphorylation GO:0001934 10 TNF MAVS IL2 IFNG F2
11 cellular response to lipopolysaccharide GO:0071222 10 TNF TLR4 TICAM1 IL10 HAVCR2
12 inflammatory response GO:0006954 9.98 TNF TLR4 TLR3 TICAM1 IL10 IKBKG
13 response to virus GO:0009615 9.96 TNF TLR3 IKBKG IFNG
14 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.96 TNF TLR4 TLR3 TICAM1 IKBKG
15 positive regulation of inflammatory response GO:0050729 9.93 TNF TLR4 TLR3 IL2
16 regulation of inflammatory response GO:0050727 9.91 TNF TLR4 GGT1
17 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.91 TNF IL2 IFNG
18 negative regulation of tumor necrosis factor production GO:0032720 9.9 TLR4 IL10 HAVCR2
19 humoral immune response GO:0006959 9.9 TNF IFNG IFNA1
20 apoptotic signaling pathway GO:0097190 9.89 TNF TLR4 TLR3 TICAM1
21 extrinsic apoptotic signaling pathway GO:0097191 9.88 TNF TLR3 IFNG
22 positive regulation of B cell proliferation GO:0030890 9.88 TLR4 TICAM1 IL2
23 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.88 TNF TLR4 TLR3 HAVCR2
24 positive regulation of interleukin-6 production GO:0032755 9.88 TNF TLR4 TLR3 TICAM1
25 positive regulation of interleukin-6 secretion GO:2000778 9.87 TNF TLR4 MAVS
26 response to exogenous dsRNA GO:0043330 9.87 TLR3 TICAM1 IFNA1
27 lipopolysaccharide-mediated signaling pathway GO:0031663 9.87 TNF TLR4 TICAM1
28 negative regulation of interferon-gamma production GO:0032689 9.85 TLR4 IL10 HAVCR2
29 positive regulation of JAK-STAT cascade GO:0046427 9.85 TNF IL10 F2
30 positive regulation of cytokine production GO:0001819 9.85 TNF TLR3 HAVCR2
31 positive regulation of tumor necrosis factor production GO:0032760 9.85 TLR4 TLR3 TICAM1 MAVS
32 microglial cell activation GO:0001774 9.84 TNF TLR3 IFNG
33 positive regulation of interleukin-12 production GO:0032735 9.83 TLR4 TLR3 IFNG
34 positive regulation of interferon-beta production GO:0032728 9.83 TLR4 TLR3 MAVS
35 positive regulation of nitric oxide biosynthetic process GO:0045429 9.83 TNF TLR4 TICAM1 IFNG
36 positive regulation of interferon-gamma production GO:0032729 9.81 TNF TLR4 IL2 HAVCR2
37 positive regulation of tumor necrosis factor secretion GO:1904469 9.8 MAVS IFNG HAVCR2
38 necroptotic process GO:0070266 9.8 TLR4 TLR3 TICAM1
39 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.8 TNF TLR4 TLR3 TICAM1 MAVS IKBKG
40 positive regulation of macrophage activation GO:0043032 9.79 TLR4 IL10 HAVCR2
41 negative regulation of interleukin-6 production GO:0032715 9.76 TNF TLR4 IL10 HAVCR2
42 toll-like receptor 3 signaling pathway GO:0034138 9.74 TLR3 TICAM1 HAVCR2
43 negative regulation of amyloid-beta clearance GO:1900222 9.73 TNF IFNG
44 macrophage activation involved in immune response GO:0002281 9.73 TICAM1 HAVCR2
45 endothelial cell apoptotic process GO:0072577 9.73 TNF IL10
46 transport GO:0006810 9.73 ALB AFP
47 necroptotic signaling pathway GO:0097527 9.72 TNF TLR3
48 negative regulation of cytokine secretion involved in immune response GO:0002740 9.72 TNF IL10
49 positive regulation of myeloid dendritic cell cytokine production GO:0002735 9.71 TICAM1 MAVS
50 positive regulation of MHC class II biosynthetic process GO:0045348 9.71 TLR4 IL10 IFNG

Molecular functions related to Hepatitis a according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.02 TNF IL2 IL10 IFNG IFNA1

Sources for Hepatitis a

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....